- Time:
The advent of recombinant antibody production in mammalian cell lines has revolutionized modern medicine. Clinical success of these agents has challenged the underlying biological manufacturing systems to produce quantities sufficient to supply the ever-expanding commercial markets. A fundamental focus for commercialization efforts was optimization of cell culture media components utilized in the biologic manufacturing process. With primary and stem cell applications poised to make similar strides in clinical progress as monoclonal antibodies did in the 1990s, manufacturing methodologies must progress in parallel to ensure the clinical success of these novel cell-based therapeutics. In this GEN webinar, we will discuss the current state of the cell culture media space for primary and stem cell expansion. Moreover, we will discuss the reagents and development strategies needed to remove serum-derived proteins from media formulations to produce chemically defined and blood component free, or blood-free, expansion processes for therapeutic cell types.
Produced with support from:
Panelists
Randall Alfano, Ph.D.
Vice President of Product Development,
InVitria
